



EXPRESS SCRIPTS®

**Express Scripts, Inc.
Pharmacy and Therapeutics Committee
Proceedings
July 18, 2009**

New Drug Evaluations

The Committee reviewed the following new drugs.

- A. **Adcirca™ (tadalafil tablets) – United Therapeutics Corporation**
- B. **Besivance™ (besifloxacin ophthalmic suspension, 0.6%) – Bausch & Lomb**
- C. **Ilaris® (canakinumab subcutaneous injection) – Novartis**
- D. **Multaq® (dronedarone tablets) – Sanofi-Aventis**
- E. **Nucynta™ (tapentadol immediate-release tablets) – PriCara**
- F. **Samsca™ (tolvaptan tablets for oral use) – Otsuka Pharmaceuticals Co.**

New Indications for Existing Products

The Committee reviewed the following new indications for existing products: [See product inserts for specific wording.]

- A. **Alimta® (pemetrexed disodium injection, powder, lyophilized, for solution for intravenous use) - Eli Lilly** - For the maintenance treatment of patients with locally advanced or metastatic nonsquamous non-small cell lung cancer whose disease has not progressed after four cycles of platinum-based first-line chemotherapy.
- B. **Axert® (almotriptan malate tablets) - Johnson & Johnson** – Acute treatment of migraine headache pain in adolescent patients age 12 to 17 years with a history of migraine attacks with or without aura usually lasting 4 hours or more (when untreated).
- C. **Azor® (amlodipine/ olmesartan medoxomil tablets) - Daiichi Sankyo** – Initial therapy in patients likely to need multiple antihypertensive agents to achieve their blood pressure goals.
- D. **Cimzia® (certolizumab pegol) - UCB Pharma** - Treatment of adults with moderately to severely active rheumatoid arthritis.
- E. **Reclast® (zoledronic acid injection) - Novartis** - For the prevention of osteoporosis in postmenopausal women.
- F. **Revatio® (sildenafil tablets)- Pfizer** – Treatment of pulmonary arterial hypertension (World Health Organization [WHO] Group I) to delay clinical worsening.
- G. **Risperdal® Consta® (risperidone long-acting injection) - Janssen** - For maintenance treatment of bipolar I disorder either as monotherapy or as adjunctive therapy to lithium or valproate.
- H. **Zemplar® (paricalcitol capsules) - Abbott Laboratories** - For the prevention and treatment of secondary hyperparathyroidism associated with chronic kidney disease Stage 5 patients on hemodialysis or peritoneal dialysis.

New Clinical Line Extensions

The Committee reviewed the following new clinical line extensions.

- A. **ACTOplus met® XR (pioglitazone hydrochloride and metformin hydrochloride extended-release tablets) - Takeda**

- B. Cetraxal[®] (ciprofloxacin 0.2% otic solution) - Laboratories SALVAT**
- C. Lamictal[®] ODT (lamotrigine orally disintegrating tablets) - GlaxoSmithKline**
- D. Lamictal[®] XR[™] (lamotrigine extended-release tablets) - GlaxoSmithKline**
- E. Tyzeka[®] (telbivudine oral solution) - Novartis Pharmaceuticals**
- F. Zipsor[™] (diclofenac potassium liquid filled capsules) - Xanodyne Pharmaceuticals**